|Articles|February 28, 2019

Identifying HIV Clusters to Help Transgender Women With HIV

Using genome sequencing, investigators have been able to identify clusters of individuals with HIV—with a particular focus on transgender women.

Although men who have sex with men (MSM) are understandably a main focus of efforts to prevent, diagnose, and treat HIV, another group—transgender women—is emerging as a population that needs more attention when it comes to preventing the spread of HIV. A new study in The Lancet HIV demonstrates that transgender women are often connected to each other, as well as to heterosexual men, in specific geographical clusters of people with HIV.

Investigators from the University of California, San Diego and Imperial College London analyzed the viral gene sequences of people living with HIV in Los Angeles with data from the Los Angeles County Department of Public Health. They discovered that out of 22,398 people studied, 8133 of them (36.3%) were sorted into 1722 separate clusters that contained between 2 and 116 people. People in a single cluster were found to have HIV gene sequences that were closely related, suggesting a pattern of transmission within the cluster.

Although transgender women were often clustered with each other, investigators also discovered that they were frequently clustered with cisgender men identifying as straight.

“Links between viruses are used as a proxy for epidemiological links, suggesting that the transmission partners of transgender women were more likely to be heterosexual men than expected,” Manon Ragonnet-Cronin, MSc, PhD, a fellow at Imperial College London and an author of the report along with Joel Wertheim, PhD, assistant professor in the Division of Infectious Diseases and Global Public Health at UC San Diego School of Medicine, told Contagion®. However, the investigators don’t know if transgender women are passing the infection to heterosexual men or vice versa. “We cannot distinguish between the transmitting and recipient partners,” she said.

Manon Ragonnet-Cronin, MSc, PhD

The team’s findings are significant because transgender women are disproportionately affected by HIV. According to the investigators, this population has an HIV rate of 27.7%, surpassing the rate even for MSM, which stands at 25%. African-American transgender women are more likely to be infected with HIV than not, with prevalence in this group as high as 56.3%. However, many transgender women are unaware they have HIV. According to the investigators’ report, testing in several major cities revealed a 12% positive rate among those who had never been tested before.

“Transgender women have higher HIV prevalence than MSM because, on average, they have more risk factors for HIV: lower socioeconomic status, involvement in sex work, drug [and] alcohol use, mental health issues, rejection from family, no [or] low access to health care, [and] more likely to be receptive anal partner,” said Dr. Ragonnet-Cronin. She added that these women often go undiagnosed because they may not feel they are the target audience for prevention campaigns.

One discovery was that younger subjects were more likely to be part of an HIV cluster than older ones. “This could mean that transmission events are happening rapidly within that group, with little time for virus evolution—therefore, clustering is indicative of rapid transmission,” said Dr. Ragonnet-Cronin. “With young people, it could also be because they have, on average, been infected for less time when they are diagnosed than older people. Therefore, the transmission events are more recent and their viruses have not had a chance to change so much.”

According to Dr. Ragonnet-Cronin and her colleagues, the hope is that this “molecular network” will be used to identify individuals who can hopefully provide information about their sexual partners, with the goal of encouraging more at-risk transgender women to get tested for HIV. A press release from the University of California-San Diego indicates that Dr. Wertheim is working with the US Centers for Disease Control and Prevention and public health departments in Chicago, New York, and Houston to use genome sequencing in those locations to identify HIV clusters and expand prevention and treatment offerings.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.